Pharmaceutical Executive, Nov 1, 2012 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Nov 1, 2012
Features
Who Pays for Specialty Medicines?
By Alison King , Lauri Mitchell
Providers and patients fish for that delicate balance between access and abandonment.
Pharm Exec's 2013 Pipeline Report
By Ben Comer
Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...
Country Report
Country Report: Czech Republic
The '90s was an enthusiastic time. With the fall of communism in 1989 and the emergence of the free economy, the international pharmaceutical industry arrived in the Czech Republic to find a highly receptive market.
Column
Market Access Roadmap
Unified payer research planning is of top import.
The Battle's on for HR Success in China
Chinese start-ups have realized that they need to recruit highly skilled and globally oriented general managers from foreign multinationals when they reach a critical size.
Agencies and Clients — Dealing with a Break-Up
By Al Topin
How an agency and client behave after they split speaks volumes about their culture and character, writes Al Topin.
OTC Crunch Time in California
Over-the-counter products face a new wave of regulation.
Prix Galien: Night at the Museum
Prix Galien celebrates a new round of next generation drug technologies.
Europe's Trust Gap
By Reflector
For the second time in recent memory, a top European regulator leaves office abruptly and under a cloud of suspicion.
Real World Insights
Commercial teams as well as patients can benefit from managed access programs.
Budgets, Biosimilars, and Bad Ads
By Jill Wechsler
While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.
From the Editor
Simple Questions for Spain
By William Looney
Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?

ADVERTISEMENT

Click here